The majority of patients (33/35, 94%) in the EVR group were treated with an ACE-inhibitor or angiotensin-receptor-antagonist from month 1 post-transplant on because of arterial hypertension, while in the control group only 49/70 patients (70%) were treated with any antihypertensive medication. Here, ACE is linked to Hypertension.